Business
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action
- Galmed KOL Symposium and Pipeline Update taking place later today at 11 a.m. Eastern time TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"text","content":"- Galmed KOL Symposium and Pipeline Update taking place later today at 11 a.m. Eastern time\n\n\nTEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced upcoming publication of a paper entitled \"Aramchol Downregulates Stearoyl CoA-Desaturase 1 (SCD1) in Hepatic Stellate Cells to Attenuate Cellular Fibrogenesis\" in the JHEP Reports. The paper is expected to be published in the JHEP Reports on January 28, 2021. \n\n \n \n \n \n \n \n\n \nThe paper summarizes a longstanding research collaboration by Prof. Scott Friedman, Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York and Prof. Jose Mato of the Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Spain describing for the first time the role of SCD1 in hepatic fibrogenesis and outlining the mechanism by which Aramchol exerts its anti-fibrotic effect directly by down regulation of SCD1 in hepatic stellate cells (HSCs). Data further support Aramchol's role in fibrosis reversal, including the potential antifibrotic activity in the ongoing Phase 3 ARMOR study in patients with NASH and fibrosis.\n\"Our findings establish a direct antifibrotic effect of Aramchol on hepatic stellate cells, the principal collagen-producing cell in liver through its inhibition of SCD1. Combined with its ability to reduce liver fat, these exciting new data establish a dual mechanism of action of Aramchol that reinforces its potential efficacy in NASH patients with fibrosis,\" said Prof. Friedman, who is also Dean for Therapeutic Discovery, Fishberg Professor of Medicine and Pharmacologic Sciences at Mount Sinai, and senior author.\nProf. Friedman will be participating in the Q&A session of Galmed's KOL Symposium and Pipeline Update taking place later today at 11am Eastern time. To register for the event, please click here.\n About Aramchol and Non-alcoholic Steatohepatitis (NASH)\nAramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of nonalcoholic steatohepatitis (\"NASH\") and fibrosis. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in anim...